Moderna (MRNA)
(Delayed Data from NSDQ)
$84.93 USD
+0.61 (0.72%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $85.09 +0.16 (0.19%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$84.93 USD
+0.61 (0.72%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $85.09 +0.16 (0.19%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
Zacks News
Coronavirus Vaccine Sales Key to Moderna's (MRNA) Q4 Earnings
by Zacks Equity Research
Investors are likely to focus on Moderna's (MRNA) sales guidance for its coronavirus vaccine in 2021 on the fourth-quarter earrings call.
Has Moderna (MRNA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (MRNA) Outperforming Other Medical Stocks This Year?
Pfizer (PFE), BioNTech Test COVID-19 Vaccine in Pregnant Women
by Zacks Equity Research
Pfizer (PFE) and BioNTech begin dosing in a mid-to-late-stage study on their COVID-19 vaccine in healthy pregnant women.
Stock Market News for Feb 19, 2021
by Zacks Equity Research
Benchmarks closed in the red on Thursday as unexpected rise in weekly initial jobless claims overshadowed promising corporate earnings results and declining number of coronavirus cases.
Tempur Sealy, Beyond Meat, Moderna, AstraZeneca and Merck highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Tempur Sealy, Beyond Meat, Moderna, AstraZeneca and Merck highlighted as Zacks Bull and Bear of the Day
4 Drug/Biotech Stocks Set to Outpace Q4 Earnings Estimates
by Kinjel Shah
Let us take a look at some drug/biotech stocks that are poised to beat on fourth-quarter earnings.
Is First Trust Multi Cap Growth AlphaDEX ETF (FAD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FAD
Moderna (MRNA) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Moderna (MRNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is a Beat in Store for Moderna (MRNA) This Earnings Season?
by Zacks Equity Research
Investor focus is likely to be on any update on the timeline of filing for emergency use authorization of Modena's (MRNA) coronavirus vaccine candidate on the fourth-quarter earrings call.
Pfizer/BioNTech to Sell More COVID-19 Vaccine Doses to EU
by Zacks Equity Research
Pfizer (PFE)/BioNTech (BNTX) win a deal for 200 million more doses of its COVID-19 vaccine in Europe.
Moderna (MRNA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed the most recent trading day at $176.76, moving -0.99% from the previous trading session.
Hedge Fund Diaries: Who Was Buying Your Stocks?
by Kevin Cook
SEC 13Fs reveal trades from months ago, but also patterns of long-term bullish behavior.
J&J (JNJ) Seeks Conditional Nod for COVID-19 Vaccine in EU
by Zacks Equity Research
J&J's (JNJ) COVID-19 vaccine, if approved, will be the only COVID-19 vaccine to be approved for single administration.
What's in the Cards for Arcturus (ARCT) This Earnings Season?
by Zacks Equity Research
Arcturus (ARCT) is likely to discuss the progress of its COVID-19 vaccine candidate on the fourth-quarter earnings call.
Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports fourth-quarter 2020 results.
What's in the Cards for Intellia (NTLA) This Earnings Season?
by Zacks Equity Research
Intellia Therapeutics (NTLA) is likely to discuss the progress of its pipeline candidate on its fourth-quarter earnings call.
What's in the Cards for Sarepta (SRPT) This Earnings Season?
by Zacks Equity Research
Sarepta Therapeutics' (SRPT) fourth-quarter results are expected to reflect the ongoing COVID-19 impact. Launch plans for casimersen is what investors are expected be focused on.
Pfizer (PFE) Gets FDA Nod for New Indication of Immunoglobulin
by Zacks Equity Research
Pfizer's (PFE) Panzyga gets FDA approval to treat chronic inflammatory demyelinating polyneuropathy (CIDP), a rare neurological disease.
Moderna (MRNA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $179.34, marking a -0.1% move from the previous day.
Henry Schein (HSIC) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Henry Schein's (HSIC) medical business' PPE sales are likely to have maintained its momentum along with global recovery trends of the dental business during Q4.
Exact Sciences (EXAS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Strength in Precision Oncology business is likely to have continued to aid Exact Sciences' (EXAS) performance in the fourth quarter of 2020 amid the coronavirus-led economic doldrums.
Are You Looking for a Top Momentum Pick? Why Moderna (MRNA) is a Great Choice
by Zacks Equity Research
Does Moderna (MRNA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Exelixis (EXEL) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on pipeline and guidance updates when Exelixis (EXEL) reports fourth-quarter 2020 results.
J&J (JNJ) Seeks Emergency Approval for Coronavirus Vaccine
by Zacks Equity Research
Johnson & Johnson (JNJ) submits regulatory application to the FDA seeking emergency use approval for its single-shot coronavirus vaccine.
Incyte (INCY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors are likely to focus on pipeline updates besides top and bottom-line numbers when Incyte (INCY) reports fourth-quarter 2020 results.